Skip to main content

Table 6 Mean difference (and 95% CI) from Baseline to 3 months (T0-T3), Baseline to 6 months (T6-T0) and 3 months to 6 months (T6-T3) within allocated group and between groups by symptom severity

From: Effectiveness of Wellbeing Intervention for Chronic Kidney Disease (WICKD): results of a randomised controlled trial

Measure

Timepoint

ISS

HepB/DSS

TAU/DSS

ISS vs HepB/DSS

ISS vs TAU/DSS

HepB/DSS vs TAU/DSS

K10 > =25

T3-T0

−2.8 (−6.1, 0.5)

−5.8 (−8.9, −2.7)**

−6.2 (−10.9, −1.5)*

3.0 (−1.5, 7.5)

3.4 (− 2.4, 9.2)

0.4 (− 5.3, 6.0)

T6-T0

−6.8 (− 10.2, −3.5)**

− 8.2 (− 11.3, − 5.1)**

−4.2 (−9.1, 0.7)

1.4 (− 3.2, 5.9)

−2.6 (− 8.5, 3.3)

− 4.0 (− 9.8, 1.8)

T6-T3

−4.0 (−7.4, −0.7)*

−2.4 (− 5.5, 0.7)

2.0 (− 3.1, 7.0)

− 1.6 (− 6.2, 3.0)

−6.0 (− 12.0, 0.1)~

−4.4 (− 10.3, 1.5)

K10 < 25

T3-T0

2.8 (0.5, 5.1)*

0.0 (− 2.4, 2.4)

3.9 (0.8, 7.0)*

2.8 (−0.5, 6.1)

− 1.2 (− 5.0, 2.7)

− 3.9 (− 7.8, 0.01)

T6-T0

2.4 (0.1, 4.8)*

−0.1 (− 2.6, 2.3)

1.3 (− 1.7, 4.4)

2.6 (− 0.8, 5.9)

1.1 (−2.7, 4.9)

− 1.5 (− 5.4, 2.4)

T6-T3

−0.3 (− 2.7, 2.0)

−0.1 (− 2.6, 2.3)

−2.6 (− 5.7, 0.5)

−0.2 (− 3.6, 3.2)

2.3 (− 1.6, 6.2)

2.5 (− 1.5, 6.4)

PHQ-9 > =10

T3-T0

−4.1 (− 6.4, − 1.8)**

−3.5 (− 5.6, − 1.5)*

1.3 (− 1.9, 4.4)

−0.5 (− 3.6, 2.5)

−5.4 (− 9.3, − 1.5)*

− 4.8 (− 8.6, − 1.1)*

T6-T0

−4.7 (− 7.0, − 2.4)**

−3.2 (− 2.2, − 1.2)*

1.4 (−1.9, 4.6)

− 1.5 (− 4.6, 1.6)

−6.1 (− 10.1, − 2.1)*

−4.6 (− 8.4, − 0.7)*

T6-T3

−0.6 (− 2.9, 1.7)

0.4 (−1.7, 2.4)

0.1 (−3.2, 3.4)

− 1.0 (− 4.1, 2.1)

−0.7 (− 4.7, 3.3)

0.3 (− 3.6, 4.1)

PHQ-9 < 10

T3-T0

2.0 (0.6, 3.4)*

0.0 (− 1.5, 1.5)

0.8 (− 1.4, 2.7)

2.0 (0.0, 4.1)

1.2 (− 1.1, 3.6)

−0.8 (− 3.2, 1.7)

T6-T0

1.5 (0.1, 2.9)*

−0.1 (− 1.6, 1.5)

0.0 (− 1.9, 2.0)

1.6 (− 0.5, 3.7)

1.5 (− 0.9, 3.8)

−0.1 (− 2.6, 2.3)

T6-T3

−0.5 (− 1.9, 0.9)

− 0.1 (− 1.6, 1.4)

−0.7 (− 2.7, 1.2)

−0.4 (− 2.5, 1.7)

0.2 (− 2.2, 2.6)

0.6 (− 1.8, 3.1)

  1. *difference is significant at p< 0.05
  2. ** difference is significant at p< 0.001